GEIGY Pharmaceuticals
As of the edition of 20 October 2026, GEIGY Pharmaceuticals runs 10 drugs, 9 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Withdrawn from market | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Diclofenac | none listed | 7 |
| Metoprolol | none listed | 0 |
| Carbamazepine | none listed | 10 |
| Baclofen | none listed | 1 |
| Clofazimine | none listed | 0 |
| Imipramine | none listed | 1 |
| Terbutaline | none listed | 0 |
| Tripelennamine | none listed | 0 |
| Phenylbutazone | none listed | 1 |
A route B row is one company at one target.
Where its trials are
- Immune system: 1 trials led
- Infections: 1 trials led
- Urinary and reproductive: 1 trials led